Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.
COVID-19
Pump head thrombosis
Thrombotic complications
V-V ECMO
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
13
7
2020
medline:
23
2
2021
entrez:
13
7
2020
Statut:
ppublish
Résumé
The novel coronavirus SARS-CoV-2 and the resulting disease COVID-19 causes pulmonary failure including severe courses requiring venovenous extracorporeal membrane oxygenation (V-V ECMO). Coagulopathy is a known complication of COVID-19 leading to thrombotic events including pulmonary embolism. It is unclear if the coagulopathy also increases thrombotic circuit complications of the ECMO. Aim of the present study therefor was to investigate the rate of V-V ECMO complications in COVID-19. We conducted a retrospective registry study including all patients on V-V ECMO treated at our centre between 01/2018 and 04/2020. COVID-19 cases were compared non- COVID-19 cases. All circuit related complications resulting in partial or complete exchange of the extracorporeal system were registered. In total, 66 patients were analysed of which 11 (16.7%) were SARS-CoV-2 positive. The two groups did not differ in clinical parameters including age (COVID-19 59.4 vs. non-COVID-19 58.1 years), gender (36.4% vs. 40%), BMI (27.8 vs. 24.2) and severity of illness as quantified by the RESP Score (1pt. vs 1pt.). 28 days survival was similar in both groups (72.7% vs. 58.2%). While anticoagulation was similar in both groups (p = 0.09), centrifugal pump head thrombosis was more frequent in COVID-19 (9/11 versus 16/55 p < 0.01). Neither the time to first exchange (p = 0.61) nor blood flow at exchange (p = 0.68) did differ in both groups. D-dimer levels prior to the thrombotic events were significantly higher in COVID-19 (mean 15.48 vs 26.59, p = 0.01). The SARS-CoV-2 induced infection is associated with higher rates of thrombotic events of the extracorporeal system during V-V ECMO therapy.
Identifiants
pubmed: 32653986
doi: 10.1007/s11239-020-02217-1
pii: 10.1007/s11239-020-02217-1
pmc: PMC7353827
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-307Références
Vetter P, Vu DL, L’Huillier AG et al (2020) Clinical features of covid-19. BMJ. https://doi.org/10.1136/bmj.m1470
doi: 10.1136/bmj.m1470
pubmed: 32303495
Guan W, Ni Z, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032
doi: 10.1056/NEJMoa2002032
Archer SL, Sharp WW, Weir EK. (2020). Differentiating COVID-19 pneumonia from acute respiratory distress syndrome (ARDS) and high altitude pulmonary edema (HAPE): therapeutic implications. Circulation CIRCULATIONAHA.120.047915.
Yang X, Yu Y, Xu J et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Res Med 8:475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
doi: 10.1016/S2213-2600(20)30079-5
Rajagopal K, Keller SP, Akkanti B, et al. (2020). Advanced pulmonary and cardiac support of COVID-19 patients: emerging recommendations from ASAIO — a living working document. circ: Heart Failure 13
Li X, Guo Z, Li B, et al. (2020). Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China: ASAIO J, 66: 475–481
Marullo AG, Cavarretta E, Biondi-Zoccai G, et al. (2020). Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience. Minerva Cardioangiol
Lodigiani C, Iapichino G, Carenzo L et al (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024
doi: 10.1016/j.thromres.2020.04.024
pubmed: 32353746
pmcid: 7177070
Helms J, Tacquard C, Severac F et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. https://doi.org/10.1007/s00134-020-06062-x
doi: 10.1007/s00134-020-06062-x
pubmed: 33141245
pmcid: 7608308
Lubnow M, Philipp A, Foltan M et al (2014) Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange – retrospective analysis of 265 cases. PLoS ONE 9:e112316. https://doi.org/10.1371/journal.pone.0112316
doi: 10.1371/journal.pone.0112316
pubmed: 25464516
pmcid: 4251903
Appelt H, Philipp A, Mueller T et al (2020) Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)—comparison of VA- versus VV ECMO. PLoS ONE 15:e0227793. https://doi.org/10.1371/journal.pone.0227793
doi: 10.1371/journal.pone.0227793
pubmed: 31986168
pmcid: 6984694
Hastings SM, Ku DN, Wagoner S et al (2017) Sources of circuit thrombosis in pediatric extracorporeal membrane oxygenation. ASAIO J 63:86–92. https://doi.org/10.1097/MAT.0000000000000444
doi: 10.1097/MAT.0000000000000444
pubmed: 27660905
Lubnow M, Philipp A, Dornia C et al (2014) d-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care 29:473.e1–473.e5. https://doi.org/10.1016/j.jcrc.2013.12.008
doi: 10.1016/j.jcrc.2013.12.008